Insight

Latest California Healthline Stories

Democrats Could Undo Trump Policies Faster, But They’re Not. Why?

The little-used Congressional Review Act allows a new administration and Congress to fast-track the repeal of regulations and other executive actions of the previous administration. But neither lawmakers nor the president are making any attempt to use it now.

KHN’s ‘What the Health?’: Getting Down to Work at HHS

After a bruising confirmation process, Xavier Becerra was sworn in as secretary of Health and Human Services this week. The Senate also confirmed the nominations of former U.S. Surgeon General Vivek Murthy to return to the post he held in the Obama administration, and former Pennsylvania health secretary Rachel Levine as assistant secretary for health. Levine is the first openly transgender person to receive Senate confirmation. Meanwhile, questions continue to swirl around the AstraZeneca covid vaccine, which some public health experts worry will create more hesitancy toward other vaccines.

Stop Blaming Tuskegee, Critics Say. It’s Not an ‘Excuse’ for Current Medical Racism.

The Tuskegee syphilis study is often cited as a reason Black Americans might hesitate to take the covid-19 vaccine. But many people say that current racism in health care and lack of access deserve more attention to move more Black Americans toward vaccine protection.

Under New Cost-Cutting Medicare Rule, Same Surgery, Same Place, Different Bill

A Trump administration Medicare rule will push some hospital patients into a Catch-22: The government says several hundred procedures no longer need to be done in a hospital, but it did not approve them to be performed elsewhere. So patients will still need to use a hospital while not officially admitted — and may be charged more out-of-pocket for the care.

Democrats Eye Medicare Negotiations to Lower Drug Prices

Progressive and conservative Democratic lawmakers, as well as President Joe Biden, are in favor of authorizing federal officials to negotiate with drugmakers over what Medicare pays for at least some of the most expensive brand-name drugs and to base those prices on the drugs’ clinical benefits. Such a measure could put Republicans in the uncomfortable position of opposing an idea that most voters from both parties generally support.

The Hype Has Faded, but Don’t Count Out Convalescent Plasma in Covid Battle

The once-promising therapy that infuses blood plasma from recovered covid-19 patients into newly infected people, theoretically to boost immunity, has suffered setbacks. But some proponents say it’s too early to abandon the treatment.